ChemioCare announces initiation of PETT based lenalidomide program
ChemioCare USA announced it is initiating development of a transdermal formulation of lenalidomide, which is currently marketed in an oral form. The benefits of transdermal delivery may transform lenalidomide PETT into a new superior drug profile.
April 23, 2019